Opendata, web and dolomites

TETRA TERMINATED

Autologous Stem Cell Seeded Tissue Engineered Trachea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TETRA project word cloud

Explore the words cloud of the TETRA project. It provides you a very rough idea of what is the project "TETRA" about.

interventions    validated    indication    dying    transplants    tissues    care    severe    trial    11    savings    conduct    follow    market    replacements    unmet    submission    48    tens    susceptible    inspire    group    treating    data    atmp    patient    benefits    bowel    orphan    poorly    pivotal    autologous    led    tetra    hospitalised    compassionate    life    length    rate    clinical    surviving    infection    reduce    seeded    insertion    eliminate    limitations    plan    airway    sme    competitor    platform    stent    accelerated    prepare    repeated    standard    strategies    scaffold    diseases    million    quality    tracheal    517    lives    disease    generate    efficacy    risk    successful    22    maa    patients    manufacturing    thousands    structural    synthetic    preliminary    commercial    stem    limited    dossier    cells    gmp    827    liver    prototype    organs    deaths    route    cell    subjected    estimate    therapeutic    surgical    20    scaffolds   

Project "TETRA" data sheet

The following table provides information about the project.

Coordinator
VIDEREGEN LIMITED 

Organization address
address: INNOVATION CENTRE 1, LIVERPOOL SCIENCE PARK, 131 M ANT
city: LIVERPOOL
postcode: L3 5TF
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.tetra-h2020.eu/
 Total cost 6˙828˙887 €
 EC max contribution 6˙828˙884 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIDEREGEN LIMITED UK (LIVERPOOL) coordinator 1˙563˙340.00
2    TMC PHARMA SERVICES LIMITED UK (Hartley Wintney) participant 1˙127˙146.00
3    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 903˙250.00
4    UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST UK (LONDON) participant 669˙578.00
5    NHS BLOOD AND TRANSPLANT UK (WATFORD) participant 535˙250.00
6    MANCHESTER UNIVERSITY NHS FOUNDATION TRUST UK (MANCHESTER) participant 483˙512.00
7    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 455˙118.00
8    INSTYTUT GRUZLICY I CHOROB PLUC PL (WARSZAWA) participant 365˙000.00
9    UNIVERSITA DEGLI STUDI DI BRESCIA IT (BRESCIA) participant 346˙266.00
10    CELL THERAPY CATAPULT LIMITED UK (LONDON) participant 281˙681.00
11    EURAM LIMITED UK (LINCOLN) participant 65˙496.00
12    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 30˙700.00
13    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 2˙546.00
14    UNIVERSITY HOSPITAL OF SOUTH MANCHESTER NHS FOUNDATION TRUST UK (MANCHESTER) participant 0.00

Map

 Project objective

CLINICAL PROBLEM AND UNMET NEED There are 11,827 patients with severe structural airway disease in Europe. Even with the current standard of care, when hospitalised this group of patients has a 22% risk of dying. Patients are currently subjected to repeated surgical interventions (stent insertion) which have a high failure rate.

Other therapeutic strategies under development include synthetic tracheal scaffolds seeded with patients own stem cells. Preliminary data show that these scaffolds are poorly integrated and are susceptible to infection.

TETRA PROJECT Our SME-led project will address the limitations of standard clinical care and competitor products under development and will: - Build on our successful compassionate use experience using autologous stem cell seeded scaffold-tracheal transplants in 48 patients - Follow on from our Phase I 4 patient INSPIRE clinical trial which will improve on the clinical prototype used in compassionate use cases - Conduct a 48 patient Phase II pivotal clinical trial to provide robust, quality data with validated GMP manufacturing processes to support an accelerated route to market for commercial exploitation in this orphan indication - Prepare a dossier for MAA submission

BENEFITS Our product, an ATMP, aims to eliminate the need for repeated surgical interventions of high risk and limited efficacy, reduce deaths and improve the quality of life for surviving patients. If treating 20% of the patients with severe structural airway disease, we estimate that in Europe our technology will improve the quality and length of patient lives and result in savings of €517 million per year.

We plan to further develop our platform technology to generate other complex tissues/organs such as bowel and liver replacements for clinical applications which will impact the lives of tens of thousands of patient in the EU with bowel and liver diseases.

 Deliverables

List of deliverables.
Project Website Websites, patent fillings, videos etc. 2019-05-31 18:06:05

Take a look to the deliverables list in detail:  detailed list of TETRA deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETRA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TETRA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More